[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T, Sobol RW, Dhir R: Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol; 2006 Nov;169(5):1812-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma.
  • In prostate adenocarcinoma, 39 microRNAs are up-regulated, and six microRNAs are down-regulated.
  • Dicer, an RNase III endonuclease, is an essential component of the microRNA machinery.
  • From a gene array analysis of 16 normal prostate tissue samples, 64 organ-confined, and four metastatic prostate adenocarcinomas, we identified an up-regulation of major components of the microRNA machinery, including Dicer, in metastatic prostate adenocarcinoma.
  • Immunohistochemical studies on a tissue microarray consisting of 232 prostate specimens confirmed up-regulation of Dicer in prostatic intraepithelial neoplasia and in 81% of prostate adenocarcinoma.
  • The increased Dicer level in prostate adenocarcinoma correlated with clinical stage, lymph node status, and Gleason score.
  • Western blot analysis of benign and neoplastic prostate cell lines further confirmed Dicer up-regulation in prostate adenocarcinoma.
  • Dicer up-regulation may explain an almost global increase of microRNA expression in prostate adenocarcinoma.
  • The presence of up-regulated microRNA machinery may predict the susceptibility of prostate adenocarcinoma to RNA interference-based therapy.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. DEAD-box RNA Helicases / metabolism. Endoribonucleases / metabolism. MicroRNAs / metabolism. Prostatic Neoplasms / enzymology. Prostatic Neoplasms / pathology. Up-Regulation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Epithelium / pathology. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Microarray Analysis. Middle Aged. Prostate / cytology. Prostate / enzymology. Prostate / pathology. Ribonuclease III

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2004 Aug;6(8):784-91 [15247924.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 16;313(3):552-4 [14697225.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3011-6 [14681208.001]
  • [Cites] Nat Neurosci. 2004 Feb;7(2):113-7 [14703574.001]
  • [Cites] Mol Biol Cell. 2004 Mar;15(3):1425-35 [14699070.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • [Cites] Eur Urol. 1996;30(2):201-5 [8875201.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1215-23 [9214605.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1735-40 [9465086.001]
  • [Cites] Nat Cell Biol. 2004 Nov;6(11):1048-53 [15516998.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Cell. 2005 Jan 14;120(1):21-4 [15652478.001]
  • [Cites] Cancer Gene Ther. 2005 Mar;12(3):217-27 [15550938.001]
  • [Cites] Cancer Sci. 2005 Feb;96(2):111-5 [15723655.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Biochem J. 2005 May 1;387(Pt 3):561-71 [15845026.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3509-12 [15867338.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Curr Opin Struct Biol. 2005 Jun;15(3):331-41 [15925505.001]
  • [Cites] BMC Cancer. 2005;5:45 [15892885.001]
  • [Cites] Cell. 2005 Jul 15;122(1):6-7 [16009126.001]
  • [Cites] J Exp Med. 2005 Jul 18;202(2):261-9 [16009718.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):740-4 [15973356.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Eur Urol. 2005 Nov;48(5):852-7 [16230228.001]
  • [Cites] Pathol Int. 2005 Nov;55(11):688-93 [16271080.001]
  • [Cites] Cancer Gene Ther. 2005 Dec;12(12):926-34 [15956982.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] Curr Biol. 2005 Dec 6;15(23):2149-55 [16289642.001]
  • [Cites] Differentiation. 2005 Dec;73(9-10):463-73 [16351690.001]
  • [Cites] Genes Dev. 2005 Dec 15;19(24):2979-90 [16357216.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):4-9 [16361094.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):179-86 [16432177.001]
  • [Cites] EMBO J. 2006 Feb 8;25(3):522-32 [16424907.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):776-80 [16495913.001]
  • [Cites] Genome Biol. 2006;7(3):210 [16584538.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2056-60 [12154197.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Cell. 2001 Jul 13;106(1):23-34 [11461699.001]
  • [Cites] Science. 2001 Aug 3;293(5531):834-8 [11452083.001]
  • [Cites] Prostate. 2002 May 1;51(2):98-107 [11948964.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):177-81 [12127403.001]
  • [Cites] Chin Med J (Engl). 2002 Apr;115(4):571-5 [12133301.001]
  • [Cites] Science. 2002 Sep 13;297(5588):1833-7 [12193640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16648-53 [12482946.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):438-42 [12600936.001]
  • [Cites] Urology. 2003 Aug;62(2):378-84 [12893368.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9779-84 [12902540.001]
  • [Cites] EMBO J. 2004 Oct 13;23(20):4051-60 [15372072.001]
  • (PMID = 17071602.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; EC 3.1.- / Endoribonucleases; EC 3.1.26.3 / DICER1 protein, human; EC 3.1.26.3 / Ribonuclease III; EC 3.6.4.13 / DEAD-box RNA Helicases
  • [Other-IDs] NLM/ PMC1780192
  •  go-up   go-down


2. Bălăşoiu M, Turculeanu A, Avrămescu C, Comănescu V, Simionescu C, Mogoantă L: Cytokines levels in prostate adenocarcinomas. Rom J Morphol Embryol; 2005;46(3):179-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokines levels in prostate adenocarcinomas.
  • In this research, we determined the levels of IL-2, IL-6 and TNF-alpha at 60 patients with prostate adenocarcinomas situated in II, III and IV stages.
  • We observed that the IL-2 levels were normal in II stage, and the levels of IL-6 and TNF-alpha were lightly increased.
  • In III and IV stages of prostate cancer the levels of IL-2 were very low and the levels of IL-6 and TNF-alpha were very increased.
  • The decrease of IL-2 levels in advanced prostate cancer goes to the decrease of immune response in prostate cancer.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / pathology. Cytokines / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444302.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-2; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


3. Ahmed H, Cappello F, Rodolico V, Vasta GR: Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer. Transl Oncol; 2009 Aug 18;2(3):146-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer.
  • Galectins, soluble intracellular and extracellular beta-galactoside-binding proteins, are known to be involved in the progression and metastasis of various cancers, including prostate adenocarcinoma, but the detailed mechanism of their biological roles remains elusive.
  • In the prostate cancer cell lines PC-3 and DU-145, galectin 3 (gal3) is present at normal levels, whereas in LNCaP, its expression is silenced.
  • On immunohistochemical analysis of normal and tumor prostate tissues, gal3 was found expressed both in nucleus and cytoplasm of benign prostatic hyperplasia, high-grade prostatic intraepithelial neoplasia, and stage I.
  • On methylation analysis, the gal3 promoter in stage II prostate adenocarcinoma (PCa) was found heavily methylated, whereas in stages III and IV, it was only lightly methylated.
  • However, in stage I PCa, both heavy and light methylations were observed in the gal3 promoter.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):567-78 [17786537.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2353-63 [10590378.001]
  • [Cites] Scand J Immunol. 2007 Aug-Sep;66(2-3):143-58 [17635792.001]
  • [Cites] Cell Mol Life Sci. 2007 Jul;64(13):1679-700 [17497244.001]
  • [Cites] Front Biosci. 2007;12:3377-97 [17485307.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 22;358(1):241-6 [17481580.001]
  • [Cites] Urology. 2007 Apr;69(4):714-20 [17445657.001]
  • [Cites] Expert Opin Ther Targets. 2007 Jan;11(1):81-90 [17150036.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Sep;6(6):533-51 [17017872.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6569-75 [16170165.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8472-8 [15623627.001]
  • [Cites] Am J Clin Pathol. 1999 May;111(5):623-31 [10230352.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):519-26 [10225438.001]
  • [Cites] J Natl Cancer Inst. 1998 Jul 1;90(13):1000-8 [9665149.001]
  • [Cites] Arch Biochem Biophys. 1998 Jan 1;349(1):7-20 [9439577.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7252-7 [8692978.001]
  • [Cites] Curr Opin Genet Dev. 1995 Jun;5(3):309-14 [7549424.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):815-22 [7677193.001]
  • [Cites] J Urol. 1994 Jun;151(6):1571-4 [7514690.001]
  • [Cites] Int J Cancer. 1994 Feb 15;56(4):474-80 [8112883.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Oncogene. 2004 Sep 30;23(45):7527-36 [15326483.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5518-22 [15328191.001]
  • [Cites] Expert Rev Mol Diagn. 2004 Jul;4(4):513-26 [15225099.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4442-52 [15231653.001]
  • [Cites] J Mol Diagn. 2004 May;6(2):101-7 [15096565.001]
  • [Cites] Glycobiology. 2004 Mar;14(3):219-32 [14693912.001]
  • [Cites] Glycoconj J. 2004;19(7-9):537-42 [14758077.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] Cancer Treat Rev. 2002 Oct;28(5):255-71 [12435372.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5400-13 [12154403.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Cell Mol Life Sci. 2002 Feb;59(2):241-57 [11915942.001]
  • [Cites] Clin Chim Acta. 2001 Nov;313(1-2):143-6 [11694252.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2727-30 [11555585.001]
  • [Cites] Histol Histopathol. 2001 Jul;16(3):861-8 [11510978.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4820-6 [11406558.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5941-5 [11085508.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):361-7 [10956411.001]
  • [Cites] Clin Chem. 2000 Aug;46(8 Pt 1):1078-84 [10926886.001]
  • [Cites] Prostate. 2000 Jul 1;44(2):118-23 [10881021.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6239-45 [10626818.001]
  • [Cites] Clin Chem. 2008 May;54(5):874-82 [18339699.001]
  • [Cites] Anticancer Agents Med Chem. 2008 Jan;8(1):22-36 [18220503.001]
  • [Cites] Urol Res. 1999 Oct;27(5):362-7 [10550525.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):605-10 [17726578.001]
  • (PMID = 19701499.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM070589
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2730137
  •  go-up   go-down


Advertisement
4. Lawton CA, DeSilvio M, Roach M 3rd, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR Jr: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys; 2007 Nov 1;69(3):646-55
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.
  • PURPOSE: This trial was designed to test the hypothesis that total androgen suppression and whole pelvic radiotherapy (WPRT) followed by a prostate boost improves progression-free survival (PFS) by > or =10% compared with total androgen suppression and prostate only RT (PORT).
  • METHODS AND MATERIALS: Patients eligible for the study included those with clinically localized adenocarcinoma of the prostate and an elevated prostate-specific antigen level of <100 ng/mL.
  • Patients were stratified by T stage, prostate-specific antigen level, and Gleason score and were required to have an estimated risk of lymph node involvement of >15%.
  • Four Phase III trials have demonstrated better outcomes when NHT was combined with RT compared with RT alone.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Control Clin Trials. 1984 Mar;5(1):55-66 [6713908.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3972-8 [14581419.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):299-307 [8420878.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):33-7 [7505775.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1035-41 [9169810.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90 [15817329.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):647-53 [17011443.001]
  • [Cites] J Urol. 1993 Dec;150(6):1923-4 [7693984.001]
  • [Cites] Control Clin Trials. 1984 Dec;5(4):348-61 [6518769.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52 [11483335.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):617-27 [10837944.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14565-70 [11734652.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):304-15 [12023134.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):103-6 [12126818.001]
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):316; author reply 316 [18406900.001]
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):315; author reply 315-6 [18406897.001]
  • (PMID = 17531401.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA096216-05S3; United States / NCI NIH HHS / CA / U56 CA096216; United States / NCI NIH HHS / CA / U56 CA096216-05S3
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS31871; NLM/ PMC2917177
  •  go-up   go-down


5. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH: The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int; 2008 Dec;102(11):1531-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
  • OBJECTIVE: To evaluate the efficacy and safety of degarelix, a new gonadotrophin-releasing hormone (GnRH) antagonist (blocker), vs leuprolide for achieving and maintaining testosterone suppression in a 1-year phase III trial involving patients with prostate cancer.
  • PATIENTS AND METHODS: In all, 610 patients with adenocarcinoma of the prostate (any stage; median age 72 years; median testosterone 3.93 ng/mL, median prostate-specific antigen, PSA, level 19.0 ng/mL) were randomized and received study treatment.
  • Degarelix represents an effective therapy for inducing and maintaining androgen deprivation for up to 1 year in patients with prostate cancer, and has a different mechanism of action from traditional GnRH agonists.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Gonadotropin-Releasing Hormone / antagonists & inhibitors. Oligopeptides / therapeutic use. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Leuprolide / therapeutic use. Male. Middle Aged. Prospective Studies. Prostate-Specific Antigen / metabolism. Testosterone / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] BJU Int. 2009 Jan;103(2):145-6 [19278531.001]
  • [CommentIn] Eur Urol. 2009 Jun;55(6):1488-9 [19650242.001]
  • (PMID = 19035858.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Oligopeptides; 0 / acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide; 33515-09-2 / Gonadotropin-Releasing Hormone; 3XMK78S47O / Testosterone; EC 3.4.21.77 / Prostate-Specific Antigen; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


6. Mitsumori M, Sasaki Y, Mizowaki T, Takayama K, Nagata Y, Hiraoka M, Negoro Y, Sasai K, Kinoshita H, Kamoto T, Ogawa O: Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure. Int J Clin Oncol; 2006 Oct;11(5):396-402
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure.
  • BACKGROUND: We herein report the clinical outcome of radical radiation therapy combined with neoadjuvant hormonal therapy (NHT) for stage III (International Union Against Cancer [UICC] 1997: UICC 97) prostate cancer.
  • Prostate-specific antigen (PSA) failure-free survival was assessed according to two different definitions, and the appropriateness of each definition is discussed.
  • METHODS: Between October 1997 and December 2000, 27 patients with stage III prostate cancer were enrolled in this study.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Biomarkers, Tumor / blood. Prostate-Specific Antigen / blood. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2001 Sep;166(3):876-81 [11490237.001]
  • [Cites] Cancer Invest. 1995;13(1):8-15 [7834477.001]
  • [Cites] Int J Clin Oncol. 2005 Dec;10(6):398-404 [16369743.001]
  • [Cites] J Urol. 1995 May;153(5):1580-6 [7714978.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):723-9 [9240638.001]
  • [Cites] Urology. 1995 Apr;45(4):616-23 [7716842.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1035-41 [9169810.001]
  • [Cites] J Urol. 1997 Oct;158(4):1623-4 [9302187.001]
  • [Cites] Urology. 1999 Aug;54(2):313-8 [10443731.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):247-52 [9069293.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1302-10 [12459350.001]
  • [Cites] Cancer J Sci Am. 1997 Mar-Apr;3(2):78-87 [9099457.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1904-11 [12743142.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3376-85 [12177097.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):251-5 [9607337.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] J Urol. 2004 Mar;171(3):1137-40 [14767287.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1053-8 [9169812.001]
  • [Cites] J Urol. 1998 Oct;160(4):1392-7 [9751362.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2740-6 [10894874.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1013-21 [9060541.001]
  • [Cites] Aktuelle Urol. 2003 Jul;34(4):259-61 [14566679.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1843-7 [12085173.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):614-20 [14529764.001]
  • [Cites] Eur Urol. 1997;32(4):385-90 [9412793.001]
  • [Cites] Scand J Urol Nephrol. 2002 Feb;36(1):28-33 [12002354.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105 [12128107.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] Jpn J Clin Oncol. 1999 Mar;29(3):151-5 [10225698.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):59-67 [14697421.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52 [11483335.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):1105-11 [8600094.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):621-8 [14529765.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):617-27 [10837944.001]
  • [Cites] N Engl J Med. 1997 Jul 31;337(5):295-300 [9233866.001]
  • (PMID = 17058138.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Biomarkers, Tumor; 33515-09-2 / Gonadotropin-Releasing Hormone; 76W6J0943E / Flutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


7. Lawton CA, Winter K, Grignon D, Pilepich MV: Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol; 2005 Feb 1;23(4):800-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.
  • PURPOSE: To update the effect of immediate androgen suppression in conjunction with standard external-beam irradiation versus radiation alone on a group of histologically lymph node-positive patients with adenocarcinoma of the prostate.
  • MATERIALS AND METHODS: A national prospective randomized trial (Radiation Therapy Oncology Group 85-31) of standard external-beam irradiation plus immediate androgen suppression versus external-beam irradiation alone was initiated in 1985 for patients with locally advanced adenocarcinoma of the prostate.
  • RESULTS: With a median follow-up of 6.5 years for all patients and 9.5 years for living patients, estimated progression-free survival with prostate-specific antigen (PSA) level less than 1.5 ng/mL at 5 and 9 years was 54% and 33%, respectively, for patients who received immediate LHRH agonist versus 10% [corrected] and 4% for patients who received radiation alone with hormonal manipulation instituted at time of relapse (P < .0001).
  • CONCLUSION: Pending the results of randomized trials, patients with adenocarcinoma of the prostate who have pathologically involved pelvic lymph nodes (pathologic node-positive or clinical stage D1) should be considered for external-beam irradiation plus immediate hormonal manipulation rather than radiation alone with hormone manipulation at the time of relapse.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Goserelin / therapeutic use. Prostatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOSERELIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2005 Dec 1;23(34):8921
  • (PMID = 15681524.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0F65R8P09N / Goserelin
  •  go-up   go-down


8. Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J, Gospodarowicz M, McLean M, Ménard C, Milosevic M, Warde P, Catton C: Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys; 2007 Nov 15;69(4):1084-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma.
  • PURPOSE: To assess in a prospective trial the feasibility and late toxicity of hypofractionated radiotherapy (RT) for prostate cancer.
  • METHODS AND MATERIALS: Eligible patients had clinical stage T1c-2cNXM0 disease.
  • The cohort had a median prostate-specific antigen value of 7.06 ng/mL.
  • The findings are being tested in an ongoing, multicenter, Phase III trial.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Aged. Biopsy. Dose Fractionation. Feasibility Studies. Humans. Male. Prospective Studies. Prostate / pathology. Prostate-Specific Antigen / blood. Salvage Therapy / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17606331.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


9. Burgess EF, Roth BJ: Changing perspectives of the role of chemotherapy in advanced prostate cancer. Urol Clin North Am; 2006 May;33(2):227-36, vii
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing perspectives of the role of chemotherapy in advanced prostate cancer.
  • The use of cytotoxic chemotherapy in advanced prostate adenocarcinoma has been validated by the recent demonstration of survival benefit in two large randomized phase III trials.
  • Before publication of these landmark trials, SWOG 9916 and TAX 327, no chemotherapeutic regimen had shown survival benefit in the treatment of androgen independent prostate cancer (AIPC).
  • Improved communication between medical and urologic oncologists and early patient referral for clinical trial participation remains essential for identifying new chemotherapeutic regimens with improved activity in AIPC and for defining the role of chemotherapy in earlier-stage disease.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631461.001).
  • [ISSN] 0094-0143
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; 35LT29625A / Estramustine; BZ114NVM5P / Mitoxantrone
  • [Number-of-references] 88
  •  go-up   go-down


10. Goodin S, Medina P, Capanna T, Shih WJ, Abraham S, Winnie J, Doyle-Lindrud S, Todd M, DiPaola RS: Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J Clin Oncol; 2005 May 20;23(15):3352-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer.
  • PURPOSE: To evaluate docetaxel in the treatment of patients with early-stage prostate cancer with prostate-specific antigen (PSA) progression after local therapy without androgen ablation therapy.
  • PATIENTS AND METHODS: Twenty-five patients with adenocarcinoma of the prostate with PSA progression despite local therapy were treated with 70 mg/m2 docetaxel every 21 days.
  • Accrual to national phase III studies in early disease is now critical and should be strongly encouraged to determine the ability of early chemotherapy to improve survival.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / administration & dosage. Neoplasms, Hormone-Dependent / drug therapy. Prostate-Specific Antigen / drug effects. Prostatic Neoplasms / drug therapy. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 May 20;23(15):3304-7 [15738547.001]
  • (PMID = 15738531.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / ODCDC CDC HHS / CC / CCSG 72,720
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Taxoids; 15H5577CQD / docetaxel; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


11. Ponz-Sarvisé M, Calvo A, Redrado M, Nguewa PA, Abella L, Catena R, García-Foncillas J, Panizo A, Gil-Bazo I: Inhibitor of differentiation-1 (Id1) characterization in poor-prognosis (PP) human bladder cancer (BCa) primary tumors and matched metastases (MTS) using a new monoclonal antibody (MoAb). J Clin Oncol; 2009 May 20;27(15_suppl):e16119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of Id1 in human cancer has been related to poor prognosis breast, prostate (Gil-Bazo, Amer Soc Clin Oncol GU.
  • 2009) and other non-adenocarcinoma tumors.
  • Most pts had PP advanced (22,7 % stage III; 68,2% stage IV) BCa.
  • CONCLUSIONS: For the first time using a MoAb against Id1 and in accord with our previous observations in prostate cancer the selection of PP pts increases tumor cell Id1 exp. from 28 up to 80%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963310.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Colonias A, Farinash L, Miller L, Jones S, Medich DS, Greenberg L, Miller R, Parda DS: Multidisciplinary treatment of synchronous primary rectal and prostate cancers. Nat Clin Pract Oncol; 2005 May;2(5):271-4; quiz 1 p following 274
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary treatment of synchronous primary rectal and prostate cancers.
  • Laboratory tests showed an elevated serum prostate-specific antigen of 32 ng/ml but other physical and medical examinations were unremarkable.
  • INVESTIGATIONS: Digital rectal examination, colonoscopy, rectal mass biopsy, endorectal ultrasound, transrectal ultrasound-guided prostate biopsy, CT scan and MRI.
  • DIAGNOSIS: Clinical stage III (T3N1M0), moderately differentiated adenocarcinoma of the rectum and clinical stage II (T1cN0M0) adenocarcinoma of the prostate.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasms, Multiple Primary / pathology. Prostatic Neoplasms / pathology. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16264963.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


13. Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC: Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther; 2009 Jun;17(6):1101-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth.
  • Prostate stem cell antigen (PSCA) is a cell surface antigen expressed in normal human prostate and over expressed in prostate cancer.
  • Elevated levels of PSCA protein in prostate cancer correlate with increased tumor stage/grade, with androgen independence and have higher expression in bone metastases.
  • In this study, the PSCA gene was isolated from the transgenic adenocarcinoma mouse prostate cell line (TRAMPC1), and a vaccine plasmid construct was generated.
  • EP-assisted delivery of the pmPSCA evoked strong specific responses and could, in neoadjuvant or adjuvant settings, provide a safe and effective immune control of prostate cancer, given that there is significant homology between human and mouse PSCA.

  • MedlinePlus Health Information. consumer health - Immunization.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1735-40 [9465086.001]
  • [Cites] Cancer Res. 1993 Jan 15;53(2):227-30 [8417812.001]
  • [Cites] C R Acad Sci III. 1998 Nov;321(11):893-9 [9879468.001]
  • [Cites] Urology. 1999 Feb;53(2):260-6 [9933036.001]
  • [Cites] J Immunol. 1961 Feb;86:228-39 [13785862.001]
  • [Cites] Prostate. 2005 Apr 1;63(1):1-12 [15378520.001]
  • [Cites] Cancer Immunol Immunother. 2005 Nov;54(11):1082-94 [16047142.001]
  • [Cites] Cell Mol Immunol. 2005 Apr;2(2):81-91 [16191413.001]
  • [Cites] Mol Ther. 2006 Feb;13(2):320-7 [16185933.001]
  • [Cites] Cancer Lett. 2006 Feb 8;232(2):300-10 [15964138.001]
  • [Cites] Curr Drug Deliv. 2006 Jan;3(1):17-28 [16472090.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1260-9 [16489082.001]
  • [Cites] Trends Mol Med. 2006 May;12(5):216-22 [16621717.001]
  • [Cites] Cancer Immunol Immunother. 2006 Nov;55(11):1443-50 [16612593.001]
  • [Cites] Cancer Gene Ther. 2006 Dec;13(12):1061-71 [16874363.001]
  • [Cites] J Immunol. 2007 Mar 1;178(5):2787-93 [17312122.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1493-502 [17332294.001]
  • [Cites] Front Biosci. 2007;12:4957-71 [17569623.001]
  • [Cites] Drug Deliv. 2007 Jul;14(5):273-7 [17613014.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(3):224-36 [17420764.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):292-300 [18172322.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):861-9 [18245488.001]
  • [Cites] Hum Gene Ther. 2008 Nov;19(11):1249-60 [19866489.001]
  • [Cites] Eur J Cancer. 1994;30A(12):1797-803 [7880609.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 15;87(4):280-5 [7707419.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Immunol Today. 1997 Apr;18(4):175-82 [9136454.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14523-8 [10588738.001]
  • [Cites] Oncogene. 2000 Mar 2;19(10):1288-96 [10713670.001]
  • [Cites] Annu Rev Immunol. 2000;18:927-74 [10837079.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46 Suppl:S52-61 [10950149.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5522-8 [11034097.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):882s-889s [11300487.001]
  • [Cites] Biol Chem. 2001 Apr;382(4):543-52 [11405219.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5857-60 [11479226.001]
  • [Cites] World J Urol. 2001 Nov;19(5):365-70 [11760786.001]
  • [Cites] Mol Ther. 2002 Feb;5(2):133-40 [11829520.001]
  • [Cites] J Biotechnol. 2002 Sep 25;98(2-3):189-98 [12141986.001]
  • [Cites] Acta Physiol Scand. 2003 Apr;177(4):437-47 [12648161.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1837-49 [12738742.001]
  • [Cites] J Surg Res. 2003 Apr;110(2):393-8 [12788670.001]
  • [Cites] Nat Rev Immunol. 2003 Aug;3(8):630-41 [12974478.001]
  • [Cites] Methods. 2003 Nov;31(3):232-42 [14511956.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):773-80 [14566827.001]
  • [Cites] JAMA. 1965 Jan 25;191(4):287-9 [5899745.001]
  • [Cites] Transplantation. 1979 Feb;27(2):127-32 [380070.001]
  • [Cites] Interferon. 1987;8:55-84 [2445689.001]
  • [Cites] Annu Rev Immunol. 1989;7:145-73 [2523712.001]
  • [Cites] Oncogene. 1998 Dec 17;17(24):3125-35 [9872328.001]
  • (PMID = 19337234.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Neoplasm Proteins; 0 / Vaccines, DNA
  • [Other-IDs] NLM/ PMC2835175
  •  go-up   go-down


14. Woodle ES, Gupta M, Buell JF, Neff GW, Gross TG, First MR, Hanaway MJ, Trofe J: Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc; 2005 Mar;37(2):958-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience.
  • INTRODUCTION: Prostate adenocarcinoma (PCA) is the second leading cause of cancer-related deaths in men, and with routine prostrate specific antigen (PSA) screening, is being diagnosed with increasing frequency.
  • Tumor recurrence rates in stage I and II disease (14 and 16%) were lower than in stage III disease (36%).
  • PCA recurrence rates are relatively low in patients who initially presented with stage I and II disease, and are half that of patients with stage III disease.
  • [MeSH-major] Adenocarcinoma / complications. Heart Transplantation. Kidney Transplantation. Liver Transplantation. Prostatic Neoplasms / complications


15. Shilo K, Dracheva T, Mani H, Fukuoka J, Sesterhenn IA, Chu WS, Shih JH, Jen J, Travis WD, Franks TJ: Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis. Arch Pathol Lab Med; 2007 Oct;131(10):1555-60
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
  • Among tumor types, 22% of squamous cell carcinoma, 56% of adenocarcinoma, 72% of typical carcinoid, 52% of atypical carcinoid, 70% of large cell neuroendocrine carcinoma, and 51% of small cell lung carcinoma were positive for AMACR.
  • Such survival advantage was seen for patients with stage I-II (P = .01) but not stage III-IV small cell carcinomas (P = .58).
  • CONCLUSIONS: These results indicate that, similar to prostate cancer, the overexpression of AMACR frequently occurs in pulmonary carcinomas.
  • Additionally, its positive correlation with outcome of stage I-II small cell lung carcinoma warrants further investigation of the AMACR role in the prognosis of this tumor.
  • [MeSH-major] Adenocarcinoma / enzymology. Biomarkers, Tumor / metabolism. Carcinoma, Neuroendocrine / enzymology. Carcinoma, Squamous Cell / enzymology. Lung Neoplasms / enzymology. Racemases and Epimerases / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922592.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


16. Kirsh VA, Peters U, Mayne ST, Subar AF, Chatterjee N, Johnson CC, Hayes RB, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst; 2007 Aug 1;99(15):1200-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of fruit and vegetable intake and risk of prostate cancer.
  • BACKGROUND: Several epidemiologic studies have reported associations between fruit and vegetable intake and reduced risk of prostate cancer, but the findings are inconsistent and data on clinically relevant advanced prostate cancer are limited.
  • METHODS: We evaluated the association between prostate cancer risk and intake of fruits and vegetables in 1338 patients with prostate cancer among 29,361 men (average follow-up = 4.2 years) in the screening arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
  • RESULTS: Vegetable and fruit consumption was not related to prostate cancer risk overall; however, risk of extraprostatic prostate cancer (stage III or IV tumors) decreased with increasing vegetable intake (RR = 0.41, 95% CI = 0.22 to 0.74, for high versus low intake; P(trend) = .01).
  • We found some evidence that risk of aggressive prostate cancer decreased with increasing spinach consumption, but the findings were not consistently statistically significant when restricted to extraprostatic disease.
  • CONCLUSION: High intake of cruciferous vegetables, including broccoli and cauliflower, may be associated with reduced risk of aggressive prostate cancer, particularly extraprostatic disease.
  • [MeSH-major] Adenocarcinoma / epidemiology. Fruit. Prostatic Neoplasms / epidemiology. Vegetables

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652276.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


17. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR: Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer; 2007 Dec 15;110(12):2691-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.
  • BACKGROUND: Greater body mass index (BMI) is associated with shorter time to prostate-specific antigen (PSA) failure following radical prostatectomy and radiation therapy (RT).
  • Whether BMI is associated with prostate cancer-specific mortality (PCSM) was investigated in a large randomized trial of men treated with RT and androgen deprivation therapy (ADT) for locally advanced prostate cancer.
  • METHODS: Between 1987 and 1992, 945 eligible men with locally advanced prostate cancer were enrolled in a phase 3 trial (RTOG 85-31) and randomized to RT and immediate goserelin or RT alone followed by goserelin at recurrence.
  • Covariates included age, race, treatment arm, history of prostatectomy, nodal involvement, Gleason score, clinical stage, and BMI.
  • CONCLUSIONS: Greater baseline BMI is independently associated with higher PCSM in men with locally advanced prostate cancer.
  • Further studies are warranted to evaluate the mechanism(s) for increased cancer-specific mortality and to assess whether weight loss after prostate cancer diagnosis alters disease course.

  • Genetic Alliance. consumer health - Obesity.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 American Cancer Society
  • [Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1240-4 [12928350.001]
  • [Cites] Lancet Oncol. 2005 Nov;6(11):841-50 [16257791.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):439-45 [14691120.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):446-53 [14691122.001]
  • [Cites] Clin Prostate Cancer. 2003 Jun;2(1):18-21 [15046678.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):6-10 [15093893.001]
  • [Cites] Urology. 1999 Nov;54(5):884-90 [10565752.001]
  • [Cites] Am J Epidemiol. 2000 Mar 15;151(6):541-9 [10733035.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89 [10995803.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):345-53 [11319175.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):599-603 [11836291.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):213-9 [12118554.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1099-106 [12122101.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):103-6 [12126818.001]
  • [Cites] JAMA. 2003 Jan 1;289(1):76-9 [12503980.001]
  • [Cites] J Urol. 2003 Apr;169(4):1308-11 [12629349.001]
  • [Cites] J Urol. 2003 May;169(5):1670-5 [12686805.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1625-38 [12711737.001]
  • [Cites] J Urol. 2004 Jun;171(6 Pt 1):2199-202 [15126785.001]
  • [Cites] JAMA. 2004 Aug 18;292(7):821-7 [15315996.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] J Chronic Dis. 1974 Sep;27(7-8):365-75 [4612056.001]
  • [Cites] Am J Epidemiol. 1984 Aug;120(2):244-50 [6465122.001]
  • [Cites] Metabolism. 1991 Jan;40(1):101-4 [1984562.001]
  • [Cites] JAMA. 1991 Feb 6;265(5):618-21 [1824790.001]
  • [Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 5;89(5):385-9 [9060961.001]
  • [Cites] Obes Res. 1998 Sep;6 Suppl 2:51S-209S [9813653.001]
  • [Cites] Urology. 2005 Jan;65(1):95-100 [15667872.001]
  • [Cites] J Urol. 2005 Mar;173(3):732-6 [15711258.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90 [15817329.001]
  • [Cites] Urology. 2005 Apr;65(4):708-12 [15833513.001]
  • [Cites] JAMA. 2005 Apr 20;293(15):1861-7 [15840860.001]
  • [Cites] JAMA. 2005 Jul 27;294(4):433-9 [16046649.001]
  • [Cites] J Urol. 2006 Feb;175(2):500-4; discussion 504 [16406980.001]
  • [Cites] JAMA. 2006 Feb 15;295(7):776-83 [16478900.001]
  • [Cites] JAMA. 2006 Apr 5;295(13):1549-55 [16595758.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1336-44 [16368750.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1305-8 [16434464.001]
  • [Cites] N Engl J Med. 2006 Aug 24;355(8):763-78 [16926275.001]
  • [Cites] N Engl J Med. 2006 Aug 24;355(8):779-87 [16926276.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):521-9 [16773619.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):631-9 [16802288.001]
  • [Cites] BJU Int. 2006 Nov;98(5):973-8 [16879443.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1977-83 [17035408.001]
  • [Cites] J Urol. 2007 Jan;177(1):102-6; discussion 106 [17162013.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):241-5 [17200361.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1192-202 [17311344.001]
  • [Cites] Cancer. 2007 Apr 15;109(8):1493-8 [17340594.001]
  • [Cites] J Urol. 2005 Sep;174(3):919-22 [16093988.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 1):1266-70 [16145390.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6889-94 [16203779.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):1062-7 [16234822.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1237-42 [14520453.001]
  • (PMID = 17999404.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA32115; United States / NCI NIH HHS / CA / K24 CA121990; United States / NCI NIH HHS / CA / K24 CA121990-02; United States / NCI NIH HHS / CA / RTOG U10 CA21661; United States / NCI NIH HHS / CA / U10 CA037422; United States / NCI NIH HHS / CA / U10 CA021661; United States / NCI NIH HHS / CA / CA121990-02; United States / NCI NIH HHS / CA / CCOP U10- CA37422; United States / NCI NIH HHS / CA / U10 CA032115
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS272555; NLM/ PMC3047389
  •  go-up   go-down


18. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, Pfeffer R, Cutajar CL, Van der Kwast T, Collette L: External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol; 2010 Nov;11(11):1066-73
Hazardous Substances Data Bank. GOSERELIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
  • BACKGROUND: We did a randomised phase 3 trial assessing the benefit of addition of long-term androgen suppression with a luteinising-hormone-releasing hormone (LHRH) agonist to external irradiation in patients with prostate cancer with high metastatic risk.
  • METHODS: For this open-label randomised trial, eligible patients were younger than 80 years and had newly diagnosed histologically proven T1-2 prostatic adenocarcinoma with WHO histological grade 3 or T3-4 prostatic adenocarcinoma of any histological grade, and a WHO performance status of 0-2.
  • Treatment allocation was open label and used a minimisation algorithm with institution, clinical stage of the disease, results of pelvic-lymph-node dissection, and irradiation fields extension as minimisation factors.
  • Patients were irradiated externally, once a day, 5 days a week, for 7 weeks to a total dose of 50 Gy to the whole pelvis, with an additional 20 Gy to the prostate and seminal vesicles.
  • 10-year overall survival was 39·8% (95% CI 31·9-47·5) in patients receiving radiotherapy alone and 58·1% (49·2-66·0) in those allocated combined treatment (HR 0·60, 95% CI 0·45-0·80, p=0·0004), and 10-year prostate-cancer mortality was 30·4% (95% CI 23·2-37·5) and 10·3% (5·1-15·4), respectively (HR 0·38, 95% CI 0·24-0·60, p<0·0001).
  • INTERPRETATION: In patients with prostate cancer with high metastatic risk, immediate androgen suppression with an LHRH agonist given during and for 3 years after external irradiation improves 10-year disease-free and overall survival without increasing late cardiovascular toxicity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy


19. Ather MH, Abbas F, Faruqui N, Israr M, Pervez S: Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol; 2008;8:21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
  • BACKGROUND: The importance of immuno-histological detection of neuroendocrine differentiation in prostatic adenocarcinoma with respect to disease at presentation and Gleason grade is gaining acceptance.
  • In the current work we have assessed the correlation of immuno-histological detection of neuroendocrine differentiation in prostatic adenocarcinoma with respect to disease at presentation and Gleason grade and to determine the relative value of various markers.
  • MATERIALS AND METHODS: Consecutive samples of malignant prostatic specimens (Transurethral resection of prostate or radical retropubic prostatectomy) from 84 patients between January 1991 and December 1998 were evaluated by immunohistochemical staining (PAP technique) using selected neuroendocrine tumor markers i.e.
  • According to the stage at diagnosis, patients were divided into three groups.
  • Group (i) included patients who had organ confined disease, group (ii) included patients with locally invasive disease, and group (iii) with distant metastasis.
  • NE expression was correlated with Gleason sum and clinical stage at presentation and analyzed using Chi-Square test and one way ANNOVA.
  • Group I had 14 patients, group II had 31 patients and group III had 39 patients.
  • Expression of CgA was seen in 7% of group I, 37% in group II and 35% of group III patients (p 0.059).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2002 Mar;440(3):241-8 [11889593.001]
  • [Cites] Eur Urol. 2003 Sep;44(3):309-14; discussion 314 [12932928.001]
  • [Cites] Semin Diagn Pathol. 2000 May;17(2):149-61 [10839615.001]
  • [Cites] Int J Urol. 2008 May;15(5):423-8 [18452460.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Urology. 2005 Aug;66(2):386-91 [16098367.001]
  • [Cites] BMC Urol. 2004 Dec 10;4(1):14 [15588310.001]
  • [Cites] Prostate Suppl. 1998;8:37-42 [9690662.001]
  • [Cites] Eur Urol. 1996;30(2):133-7 [8875193.001]
  • [Cites] Cancer. 1992 Jul 1;70(1 Suppl):254-68 [1350941.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):512-5 [11792908.001]
  • [Cites] Endocr Pathol. 2003 Winter;14(4):293-301 [14739487.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3943-53 [15217924.001]
  • [Cites] Adv Anat Pathol. 2004 Jul;11(4):175-89 [15220821.001]
  • [Cites] Prog Clin Biol Res. 1987;243A:529-31 [2889216.001]
  • [Cites] Br J Urol. 1991 Sep;68(3):258-62 [1913066.001]
  • [Cites] Int J Cancer. 1995 Jul 28;62(3):252-8 [7543077.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1240-6 [7977947.001]
  • (PMID = 19115997.001).
  • [ISSN] 1471-2490
  • [Journal-full-title] BMC urology
  • [ISO-abbreviation] BMC Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Other-IDs] NLM/ PMC2628675
  •  go-up   go-down


20. Severi G, Shannon BA, Hoang HN, Baglietto L, English DR, Hopper JL, Pedersen J, Southey MC, Sinclair R, Cohen RJ, Giles GG: Plasma concentration of Propionibacterium acnes antibodies and prostate cancer risk: results from an Australian population-based case-control study. Br J Cancer; 2010 Jul 27;103(3):411-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma concentration of Propionibacterium acnes antibodies and prostate cancer risk: results from an Australian population-based case-control study.
  • BACKGROUND: Recent studies in prostatic tissue suggest that Propionibacterium acnes (P. acnes), a bacterium associated with acne that normally lives on the skin, is the most prevalent bacterium in the prostate and in men with benign prostatic hyperplasia.
  • Its prevalence is higher in samples from patients subsequently diagnosed with prostate cancer.
  • The aim of our study was to test whether circulating levels of P. acnes antibodies are associated with prostate cancer risk and tumour characteristics using plasma samples from a population-based case-control study.
  • The odds ratio for prostate cancer associated with titres at or above the median value was 0.73 (95% CI 0.58-0.91, P=0.005).
  • The association appeared to be particularly strong for advanced prostate cancer (AJCC Stage grouping III-IV) for which the odds ratio was 0.59 (95% CI 0.43-0.81, P=0.001) but there was insufficient evidence that the association differed by tumour stage (p heterogeneity=0.07).
  • CONCLUSION: These results need to be confirmed in prospective studies but they are consistent with the hypothesis that P. acnes has a role in prostate cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Antibodies, Bacterial / blood. Propionibacterium acnes / immunology. Prostatic Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2688-92 [17724724.001]
  • [Cites] Med Hypotheses. 2007;69(4):960-1 [17056188.001]
  • [Cites] Immunol Rev. 2008 Apr;222:145-54 [18363999.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3254-61 [18519750.001]
  • [Cites] Prostate. 2000 Sep 1;44(4):271-4 [10951490.001]
  • [Cites] Ann Oncol. 2001 Jun;12(6):761-5 [11484949.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):241-5 [12455039.001]
  • [Cites] J Natl Cancer Inst. 2003 Jun 4;95(11):818-24 [12783937.001]
  • [Cites] J Invest Dermatol. 2003 Nov;121(5):1226-8 [14708633.001]
  • [Cites] Immunology. 2004 Jul;112(3):352-63 [15196202.001]
  • [Cites] Ann Epidemiol. 2004 Oct;14(9):655-62 [15380796.001]
  • [Cites] Br J Dermatol. 1987 Jun;116(6):805-12 [2956986.001]
  • [Cites] Br J Urol. 1990 Jun;65(6):606-10 [1695535.001]
  • [Cites] J Urol. 2005 Jun;173(6):1969-74 [15879794.001]
  • [Cites] Am J Epidemiol. 2005 Jun 15;161(12):1094-101 [15937017.001]
  • [Cites] Cancer Causes Control. 2006 Nov;17(9):1127-33 [17006718.001]
  • [Cites] Scand J Immunol. 2007 Jun;65(6):538-48 [17523946.001]
  • [Cites] Front Biosci. 2007;12:4957-71 [17569623.001]
  • [Cites] BJU Int. 2008 Feb;101(4):429-35 [17850358.001]
  • (PMID = 20606679.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bacterial
  • [Other-IDs] NLM/ PMC2920014
  •  go-up   go-down


21. Chen C, Chen LQ, Chen LD, Yang GL, Li Y: Evaluation of tumor markers biochip C12 system in the diagnosis of gastric cancer and the strategies for improvement: analysis of 100 cases. Hepatogastroenterology; 2008 May-Jun;55(84):991-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODOLOGY: Sera from 100 gastric carcinoma patients were screened for 12 tumor markers including carcinoembryonic antigen, alpha-fetoprotein, carbohydrate antigen 19-9, carbohydrate antigen 242, cancer antigen 15-3, cancer antigen 125, prostate specific antigen, free-PSA, neuron-specific enolase, human chorionic gonagotropin-beta, human growth hormone, and ferritin, using the C12 biochip system.
  • RESULTS: The overall diagnostic rate of C12 biochip system was 37%, and 7.8%, 29.4%, 35.5% and 50%, respectively, for stages I, II, III and IV patients.
  • The differences in diagnostic rates between stage I (7.8%) and stage IV (50%) reached statistical significance (chi-square test, Chi2=7.20, p<0.01).
  • CONCLUSIONS: The C12 biochip system has some value in the diagnosis of advanced stage gastric cancer, but less sensitive in early gastric cancer.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Carcinoma / diagnosis. Carcinoma / pathology. Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / pathology. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705314.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


22. Chen C, Chen LQ, Yang GL, Li Y: Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases. Ai Zheng; 2007 Nov;26(11):1221-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twelve tumor markers were detected in the sera of 130 pathologically confirmed CRC patients, including carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 242 (CA242), cancer antigen 15-3 (CA15-3), cancer antigen 125 (CA125), prostate specific antigen (PSA), free-PSA(f-PSA), neuron-specific enolase (NSE), human chorionic gonagotropin-beta (beta-HCG), human growth hormone (HGH), and ferritin, using the C12 diagnostic biochip system.
  • RESULTS: The overall diagnostic rate for the 130 patients was 42.3%; and the diagnostic rates were 13.6%, 39.5%, 38.2% and 68.8%, for stages I, II, III and IV patients, respectively.
  • There was significant difference in the diagnostic rates between stage I and stage IV patients.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Colorectal Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Antigens, Tumor-Associated, Carbohydrate / blood. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prostate-Specific Antigen / blood. Protein Array Analysis. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991322.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA 242 antigen; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


23. Sobczuk A, Smolarz B, Romanowicz-Makowska H, Pertyński T: MMAC/PTEN gene expression in endometrial cancer: RT-PCR studies. Pol J Pathol; 2006;57(3):137-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations in the MMAC/PTEN (phosphatase and tensin homologue deleted on chromosome 10) gene are documented in cancers of the breast, prostate, ovary, colon, melanoma, glioblastoma, lymphoma and endometrium.
  • In the present work MMAC/PTEN gene expression in women with endometrial adenocarcinoma (n=70) in RNA samples obtained from cancer tissue were investigated.
  • The expression of MMAC/PTEN gene in endometrial adenocarcinoma cases was significantly reduced compared to the expression in the normal samples (P < 0.05).
  • Furthermore the significant difference (P < 0.05) was observed between the expression of MMAC/PTEN in stage III versus lower stages of endometrial cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Endometrial Neoplasms / genetics. Gene Expression. PTEN Phosphohydrolase / genetics

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17219740.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


24. Liebig C, Ayala G, Wilks J, Verstovsek G, Liu H, Agarwal N, Berger DH, Albo D: Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol; 2009 Nov 1;27(31):5131-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a subset analysis comparing patients with node-negative disease with patients with stage III disease, the 5-year disease-free survival rate was 56% for stage III patients versus 29% for patients with node-negative, PNI-positive tumors (P = .0002).
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Peripheral Nerves / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1986 Oct;96(10):1145-8 [3762289.001]
  • [Cites] Head Neck Surg. 1986 Jul-Aug;8(6):401-8 [3721882.001]
  • [Cites] Dis Colon Rectum. 1991 Sep;34(9):798-804 [1914747.001]
  • [Cites] Br J Cancer. 1992 Jan;65(1):102-7 [1733432.001]
  • [Cites] Am J Surg Pathol. 1993 Apr;17(4):336-41 [8494103.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):46-50 [8653361.001]
  • [Cites] Pancreas. 1996 May;12(4):357-61 [8740402.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1267-71 [8826950.001]
  • [Cites] Dis Colon Rectum. 1997 Mar;40(3):326-31 [9118749.001]
  • [Cites] J Surg Oncol. 1997 Jul;65(3):164-70 [9236924.001]
  • [Cites] Mol Cell Endocrinol. 1997 Oct 31;134(1):15-22 [9406845.001]
  • [Cites] Oncol Rep. 1998 Jan-Feb;5(1):73-6 [9458297.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Jun;124(6):637-40 [9639472.001]
  • [Cites] Am J Surg. 1999 May;177(5):392-5 [10365877.001]
  • [Cites] Clin Exp Metastasis. 2004;21(4):285-92 [15554384.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):354-9 [15737030.001]
  • [Cites] Cell Death Differ. 2005 Aug;12(8):1044-56 [16015381.001]
  • [Cites] Cancer. 2007 Jan 1;109(1):13-24 [17123267.001]
  • [Cites] Am J Clin Oncol. 2007 Feb;30(1):93-6 [17278901.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Dis Colon Rectum. 2008 May;51(5):503-7 [18322753.001]
  • [Cites] Colorectal Dis. 2008 Nov;10(9):879-86 [19037929.001]
  • [Cites] Acta Chir Iugosl. 2008;55(3):39-44 [19069691.001]
  • [Cites] Cancer. 2009 Aug 1;115(15):3379-91 [19484787.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):34-63 [16019758.001]
  • [Cites] Cancer. 1988 Mar 1;61(5):1018-23 [3338045.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1985 Jul-Aug;94(4 Pt 1):426-7 [4026129.001]
  • [Cites] Dig Dis. 1999;17(2):67-79 [10545712.001]
  • [Cites] Urology. 1999 Dec;54(6):1039-43 [10604705.001]
  • [Cites] J Urol. 2001 Jan;165(1):114-8 [11125378.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G958-67 [11292605.001]
  • [Cites] Eur Urol. 2001 Sep;40(3):308-12 [11684847.001]
  • [Cites] Dis Colon Rectum. 2001 Nov;44(11):1682-8 [11711742.001]
  • [Cites] Prostate. 2001 Nov 1;49(3):213-23 [11746267.001]
  • [Cites] Digestion. 2002;66(2):79-88 [12428066.001]
  • [Cites] Urology. 2003 Apr;61(4):870-5 [12670591.001]
  • [Cites] Pancreas. 2003 May;26(4):322-5 [12717262.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):19-24 [14697416.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jun;34(6):323-8 [15333684.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6082-90 [15342391.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2004 Sep;280(1):821-6 [15382019.001]
  • [CommentIn] Z Gastroenterol. 2010 Dec;48(12):1405-6 [21125515.001]
  • [CommentIn] J Clin Oncol. 2010 Jul 20;28(21):e358-60; author reply e361-2 [20385977.001]
  • (PMID = 19738119.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2773472
  •  go-up   go-down


25. Shanmugam C, Jhala NC, Katkoori VR, Wan W, Meleth S, Grizzle WE, Manne U: Prognostic value of mucin 4 expression in colorectal adenocarcinomas. Cancer; 2010 Aug 01;116(15):3577-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients who had early stage tumors (stages I and II) with high MUC4 expression had a shorter disease-specific survival (log-rank; P=.007) than patients who had with low expression.
  • Patients who had advanced-stage CRCs (stages III and IV) did not demonstrate such a difference (log-rank; P=.108).
  • Multivariate regression models that were generated separately for patients with early stage and advanced-stage CRC confirmed that increased expression of MUC4 was an independent indicator of a poor prognosis only for patients who had early stage CRCs (hazard ratio, 3.77; 95% confidence interval, 1.46-9.73).
  • CONCLUSIONS: The current results indicated that increased MUC4 expression is a predictor of poor survival in CRC, specifically for patients who have early stage tumors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Cancer Society.
  • [Cites] Gastroenterology. 1994 Apr;106(4):1054-61 [8143972.001]
  • [Cites] Cancer Res. 1992 Nov 1;52(21):5971-8 [1394223.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1054-9 [8683636.001]
  • [Cites] J Clin Pathol. 1996 Jul;49(7):560-4 [8813954.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):346-58 [9221816.001]
  • [Cites] J Histochem Cytochem. 1999 Aug;47(8):1063-74 [10424891.001]
  • [Cites] Cancer. 2005 May 15;103(10):2163-70 [15816050.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):806-13 [15897748.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):881-9 [15958852.001]
  • [Cites] J Clin Pathol. 2005 Aug;58(8):845-52 [16049287.001]
  • [Cites] Prostate. 2006 Mar 1;66(4):421-9 [16302265.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4257-64 [16857800.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1386-94 [16880776.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]
  • [Cites] Lung Cancer. 2007 Feb;55(2):195-203 [17126950.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]
  • [Cites] Arch Pathol Lab Med. 2007 Apr;131(4):593-8 [17425390.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):309-20 [17406026.001]
  • [Cites] Eur J Clin Invest. 2007 May;37(5):416-24 [17461988.001]
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):345-57 [17595659.001]
  • [Cites] J Histochem Cytochem. 2008 Mar;56(3):305-12 [18071066.001]
  • [Cites] FASEB J. 2008 Apr;22(4):966-81 [18024835.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2065-70 [18381409.001]
  • [Cites] Eur J Cancer. 2008 May;44(7):1048-56 [18397823.001]
  • [Cites] FASEB J. 2008 Aug;22(8):3035-45 [18492726.001]
  • [Cites] Oncol Rep. 2009 Jan;21(1):49-56 [19082442.001]
  • [Cites] Br J Cancer. 2009 Jan 27;100(2):344-51 [19127263.001]
  • [Cites] Dig Dis. 1999;17(2):67-79 [10545712.001]
  • [Cites] Histopathology. 2000 Feb;36(2):121-6 [10672056.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4017-25 [11051251.001]
  • [Cites] Oncogene. 2001 Jan 25;20(4):461-70 [11313977.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4033-40 [11751498.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] J Histochem Cytochem. 2004 Feb;52(2):253-61 [14729877.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):150-7 [14657954.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] Head Neck. 2004 Apr;26(4):353-64 [15054739.001]
  • [Cites] Laryngoscope. 2004 Aug;114(8 Pt 2 Suppl 101):1-32 [15284539.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1633-8 [15494719.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):953-64 [7657125.001]
  • (PMID = 20564074.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U54 CA118623; United States / NCI NIH HHS / CA / U54 CA118948; United States / NCI NIH HHS / CA / 2U54-CA118948-03; United States / NCI NIH HHS / CA / R01 CA098932; United States / NCI NIH HHS / CA / U24-CA086359; United States / NCI NIH HHS / CA / R01-CA98932-01; United States / NCI NIH HHS / CA / R03-CA139629-01; United States / NCI NIH HHS / CA / R03 CA139629; United States / NCI NIH HHS / CA / R03 CA139629-01; United States / NCI NIH HHS / CA / U24 CA086359
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucin-4
  • [Other-IDs] NLM/ NIHMS189749; NLM/ PMC2910814
  •  go-up   go-down


26. Blum KA, Johnson JL, Niedzwiecki D, Piro LD, Saven A, Peterson BA, Byrd JC, Cheson BD, Cancer and Leukemia Group B Study 9153: Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Cancer; 2006 Dec 15;107(12):2817-25
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: For this multicenter, single-arm, Phase II study, 44 patients with treatment-naive, stage III or IV, indolent NHL (International Working Formulation subtypes A, B, and C) were enrolled.
  • Four late malignancies (prostate adenocarcinoma, ductal carcinoma in situ, and myelodysplasia) and 4 patients with large cell transformation were reported.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 17120198.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA04457; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA26806; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA47555; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / CA77658
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine
  •  go-up   go-down


27. Zou YP, Li WM, Zheng F, Li FC, Huang H, Du JD, Liu HR: Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer. World J Gastroenterol; 2010 Oct 28;16(40):5104-10
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rate of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) in 32 patients was 21.8% (7/32), 56.3% (18/32), 15.6% (5/32) and 6.3% (2/32), respectively, 6 mo after operation, with a median overall survival time of 17. 5 mo.
  • The median survival time of patients at stage III was longer than that of those at stage IV (19 mo vs 10 mo, P = 0.0026).
  • CONCLUSION: Intraoperative RFA combined with (125)iodine seed implantation is a feasible and safe procedure for unresectable pancreatic cancer with acceptable minor complications, and can prolong the survival time of patients, especially those at stage III.
  • [MeSH-major] Adenocarcinoma / therapy. Catheter Ablation / methods. Iodine Radioisotopes / therapeutic use. Pancreatic Neoplasms / therapy. Radiotherapy / methods

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Feb 1;97(3):554-60 [12548596.001]
  • [Cites] Breast Cancer. 2003;10(1):4-9 [12525756.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1346-52 [12599244.001]
  • [Cites] Eur J Surg Oncol. 2004 Feb;30(1):85-7 [14736529.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Lancet. 1974 Nov 9;2(7889):1127-31 [4139420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):931-5 [2808054.001]
  • [Cites] Ann Surg. 1990 Aug;212(2):132-9 [1695834.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):305-11 [1587751.001]
  • [Cites] Lifetime Data Anal. 1999;5(1):81-90 [10214004.001]
  • [Cites] Gastrointest Endosc. 1999 Sep;50(3):392-401 [10462663.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Dec;47(6):325-8 [15674746.001]
  • [Cites] Clin Liver Dis. 2005 May;9(2):301-14, viii [15831275.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1281-92 [16001679.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1345-50 [16029791.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Aug;5(4):657-66 [16111466.001]
  • [Cites] Invest Radiol. 2005 Sep;40(9):583-90 [16118551.001]
  • [Cites] Prostate. 2005 Nov 1;65(3):260-7 [16015591.001]
  • [Cites] Eur J Radiol. 2005 Dec;56(3):403-8 [15964164.001]
  • [Cites] JOP. 2006;7(1):1-4 [16407612.001]
  • [Cites] JOP. 2006;7(1):74-8 [16407624.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):485-90 [16615151.001]
  • [Cites] Langenbecks Arch Surg. 2007 Jan;392(1):55-60 [17089173.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):327-34 [17674961.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1224-30 [18381371.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5513-8 [19858379.001]
  • [Cites] Pancreas. 2000 Jan;20(1):14-20 [10630378.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Arch Surg. 2000 Mar;135(3):332-5 [10722037.001]
  • [Cites] Acta Chir Iugosl. 2002;49(3):19-24 [12587443.001]
  • (PMID = 20976848.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Other-IDs] NLM/ PMC2965288
  •  go-up   go-down


28. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K: Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer; 2006;5:62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The involvement of the cyclooxygenases (COX), in particular COX-2, is well documented for many tumours, e.g. colon, breast and prostate cancer, by both experimental and clinical studies.
  • The increase of COX-2 was also correlated to stage (FIGO classification) with significant elevations in stages II and III.
  • EP1 was increased in stage III while no significant alterations were demonstrated for COX-1, mPGES-1 or EP2 for stage.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / metabolism. Densitometry. Disease Progression. Epithelial Cells / pathology. Female. Humans. Immunoblotting. Immunohistochemistry. Intramolecular Oxidoreductases / metabolism. Neoplasm Staging. Ovary / metabolism. Receptors, Prostaglandin E / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Soc Gynecol Investig. 2002 May-Jun;9(3):168-73 [12009392.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2002;21(2):149-53 [12086401.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1205-11 [12181243.001]
  • [Cites] J Reprod Immunol. 2002 Oct-Nov;57(1-2):47-60 [12385833.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1423-9 [14508829.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1298-304 [14520463.001]
  • [Cites] Prog Lipid Res. 2004 Jan;43(1):3-35 [14636669.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8653-61 [14647459.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2607-23 [14669280.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):309-13 [14719060.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):538-45 [14760075.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):622-7 [14766256.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4670-9 [15269139.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Sep;83(9):783-95 [15315588.001]
  • [Cites] Reproduction. 2004 Nov;128(5):607-14 [15509706.001]
  • [Cites] Lancet. 1971 Jul 17;2(7716):163 [4104488.001]
  • [Cites] Gynecol Oncol. 1983 Dec;16(3):340-5 [6360817.001]
  • [Cites] Gynecol Obstet Invest. 1984;18(5):225-9 [6396175.001]
  • [Cites] Prostaglandins. 1985 May;29(5):665-72 [3859890.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):275-80 [9221804.001]
  • [Cites] J Histochem Cytochem. 1998 Jan;46(1):77-84 [9405496.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1240-8 [10098766.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10501-6 [10468638.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1927-33 [15870720.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Aug;73(2):103-11 [15963707.001]
  • [Cites] Oncogene. 2005 Dec 1;24(54):7991-8002 [16044148.001]
  • [Cites] Nucleic Acids Res. 2006;34(1):217-31 [16397300.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1884-91 [16287068.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2527-31 [16510568.001]
  • [Cites] Curr Pharm Des. 2006;12(8):943-54 [16533161.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Obstet Gynecol. 2005 Mar;192(3):819-25 [15746677.001]
  • [Cites] Oncol Rep. 2005 Apr;13(4):559-83 [15756426.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3735-44 [15867369.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3250-6 [15867220.001]
  • [Cites] J Reprod Fertil. 2000 Mar;118(2):375-85 [10864803.001]
  • [Cites] Epidemiology. 2000 Mar;11(2):111-7 [11021606.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):849-53 [11238034.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:661-90 [11264472.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2328-34 [11280806.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Int J Mol Med. 2001 Jul;8(1):31-6 [11408945.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2496-504 [11489832.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7305-9 [11585770.001]
  • [Cites] Int J Mol Med. 2001 Dec;8(6):603-6 [11712072.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):202-9 [11801560.001]
  • [Cites] Annu Rev Physiol. 2002;64:69-92 [11826264.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):893-903 [11891188.001]
  • (PMID = 17107625.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Prostaglandin E; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / prostaglandin-E synthase; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC1657027
  •  go-up   go-down


29. Liang JT, Lai HS, Lee PH, Chang KJ: Laparoscopic pelvic autonomic nerve-preserving surgery for sigmoid colon cancer. Ann Surg Oncol; 2008 Jun;15(6):1609-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The genitourinary function was evaluated on the basis of validated questionnaires including International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF), and Female Sexual Function Index (FSFI).
  • RESULTS: A total of 112 patients (tumor, node, metastasis system stage I, n = 8; stage II, n = 54; stage III, n = 50; male, n = 58; female, n = 54; age [mean +/- standard deviation], 55.8 +/- 6.4 years) with good baseline genitourinary function were operated on with the intent of total preservation of pelvic autonomic nerves and curative resection of sigmoid colon cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Autonomic Pathways / surgery. Colectomy. Sigmoid Neoplasms / surgery. Trauma, Nervous System / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2004 Apr;91(4):465-8 [15048749.001]
  • [Cites] Tech Coloproctol. 2003 Apr;7(1):29-33 [12750952.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2354-61 [16408331.001]
  • [Cites] Br J Surg. 2005 Nov;92(11):1444-8 [16184622.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1124-32 [15997446.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):212-23 [16041212.001]
  • [Cites] World J Surg. 2003 Feb;27(2):190-6 [12616435.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1178-85 [12352233.001]
  • [Cites] J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208 [10782451.001]
  • [Cites] Semin Surg Oncol. 2000 Apr-May;18(3):235-43 [10757889.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1354-7 [15362751.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2206-14 [9951896.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1285-7 [17235719.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):109-17 [17066227.001]
  • [Cites] Int J Clin Oncol. 2006 Oct;11(5):339-43 [17058130.001]
  • [Cites] Dis Colon Rectum. 2004 Sep;47(9):1442-7 [15486739.001]
  • [Cites] Ann Surg. 1988 Oct;208(4):391-400 [3178328.001]
  • [Cites] Dis Colon Rectum. 1995 Nov;38(11):1162-8 [7587758.001]
  • [Cites] Cancer. 1996 Nov 1;78(9):1871-80 [8909305.001]
  • [Cites] Br J Surg. 1997 Apr;84(4):586-7 [9112939.001]
  • [Cites] Urology. 1997 Jun;49(6):822-30 [9187685.001]
  • [Cites] Br J Surg. 1998 Aug;85(8):1162 [9718031.001]
  • (PMID = 18365285.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2373867
  •  go-up   go-down






Advertisement